ATE177078T1 - Amidino-derivate als no-synthetase inhibitoren - Google Patents

Amidino-derivate als no-synthetase inhibitoren

Info

Publication number
ATE177078T1
ATE177078T1 AT94931893T AT94931893T ATE177078T1 AT E177078 T1 ATE177078 T1 AT E177078T1 AT 94931893 T AT94931893 T AT 94931893T AT 94931893 T AT94931893 T AT 94931893T AT E177078 T1 ATE177078 T1 AT E177078T1
Authority
AT
Austria
Prior art keywords
synthetase inhibitors
amidino derivatives
derivatives
amidino
chem
Prior art date
Application number
AT94931893T
Other languages
English (en)
Inventor
Donald W Hansen Jr
Mark G Currie
E Ann Hallinan
Kam F Fok
Timothy J Hagen
Arija A Bergmanis
Steven W Kramer
Len F Lee
Suzanne Metz
William M Moore
Karen B Peterson
Barnett S Pitzele
Dale P Spangler
R Keith Webber
Mihaly V Toth
Mahima Trivedi
Foe S Tjoeng
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE177078T1 publication Critical patent/ATE177078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/46—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94931893T 1993-10-21 1994-10-20 Amidino-derivate als no-synthetase inhibitoren ATE177078T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14116893A 1993-10-21 1993-10-21

Publications (1)

Publication Number Publication Date
ATE177078T1 true ATE177078T1 (de) 1999-03-15

Family

ID=22494486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931893T ATE177078T1 (de) 1993-10-21 1994-10-20 Amidino-derivate als no-synthetase inhibitoren

Country Status (15)

Country Link
US (4) US5854234A (de)
EP (2) EP0897912A1 (de)
JP (1) JPH09504028A (de)
KR (1) KR100342275B1 (de)
CN (1) CN1077886C (de)
AT (1) ATE177078T1 (de)
AU (1) AU688811B2 (de)
CA (1) CA2173468A1 (de)
DE (1) DE69416848T2 (de)
DK (1) DK0724570T3 (de)
ES (1) ES2129679T3 (de)
GR (1) GR3030167T3 (de)
NO (1) NO309303B1 (de)
RU (1) RU2136661C1 (de)
WO (1) WO1995011231A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69416848T2 (de) * 1993-10-21 1999-07-08 Searle & Co Amidino-derivate als no-synthetase inhibitoren
US5807886A (en) * 1994-05-07 1998-09-15 Astra Aktiebolag Bicyclic amidine dervatives as inhibitors of nitric oxide synthetase
US5629322A (en) * 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
DE4442116A1 (de) * 1994-11-25 1996-05-30 Cassella Ag 2-Amino-1,3-thiazine als Hemmstoffe der Stickstoffmonoxid-Synthase
JPH08333258A (ja) * 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
FR2728261A1 (fr) * 1994-12-14 1996-06-21 Japan Tobacco Inc Derives de thiazine ou de thiazepine utiles comme inhibiteurs de la no-synthetase
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
AU712315B2 (en) * 1995-04-20 1999-11-04 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
AU712995B2 (en) * 1995-05-10 1999-11-18 G.D. Searle & Co. Nitric oxide synthase inhibitors derived from cyclic amidines
AU6945096A (en) * 1995-09-14 1997-04-01 Nippon Kayaku Kabushiki Kaisha Nitrogen monoxide synthetase inhibitor comprising 2-aminopyridines as active ingredient
JP3188715B2 (ja) * 1995-11-01 2001-07-16 メルク エンド カンパニー インコーポレーテッド 一酸化窒素シンターゼの阻害物質としてのヘキサヒドロ−５−イミノ−１，４−ヘテロアゼピン誘導体
US6043358A (en) * 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
DK0891332T3 (da) * 1996-03-29 2004-07-05 Pfizer 6-phenylpyridyl-2-aminderivater
CN1221407A (zh) * 1996-04-13 1999-06-30 英国阿斯特拉药品有限公司 氨基异喹啉和氨基噻吩并吡啶衍生物及其作为抗炎剂的用途
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
JP3505189B2 (ja) * 1997-02-10 2004-03-08 ファイザー・プロダクツ・インク ２−アミノ−６−（２−置換−４−フェノキシ）−置換ピリジン
US6110930A (en) 1997-04-10 2000-08-29 Ono Pharmaceutical Co., Ltd. Condensed piperidine compound
SE9701681D0 (sv) 1997-05-05 1997-05-05 Astra Ab New compounds
SE9701682D0 (sv) * 1997-05-05 1997-05-05 Astra Ab Compounds
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
US6552052B2 (en) 1998-06-10 2003-04-22 Monsanto/G.D. Searle Pyrrolo[2,1-c][1,2,4] thiadiazoles and Pyrollo[2,1-c][1,12,4]oxadiazoles useful as nitric oxide synthase inhibitors
JP2002517502A (ja) * 1998-06-10 2002-06-18 ジー・ディー・サール・アンド・カンパニー 複素二環状及び三環状一酸化窒素シンターゼ阻害剤
DE19844291A1 (de) * 1998-09-18 2000-03-23 Schering Ag Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln
WO2000061558A1 (fr) * 1999-04-09 2000-10-19 Mochida Pharmaceutical Co., Ltd. Remedes pour douleurs neurogenes
SE9901530D0 (sv) * 1999-04-28 1999-04-28 Astra Pharma Prod Novel compounds
KR100835265B1 (ko) 2000-03-24 2008-06-09 파마시아 코포레이션 산화 질소 신타아제 억제제로 유용한 아미디노 화합물 및그들의 염
US7087633B2 (en) * 2000-03-31 2006-08-08 Universitair Medisch Centrum Method for treating perinatal asphyxia in a human or animal neonate
EP1280526B1 (de) * 2000-03-31 2005-06-01 Universitair Medisch Centrum Utrecht Verwendung von 2-iminobiotin zur herstellung eines arzneimittels zur prävention und / oder therapie von komplikationen bei neugeborenen, die während der geburt entstanden sind
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
US6956131B2 (en) 2000-04-13 2005-10-18 Pharmacia Corporation 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6451821B1 (en) 2000-06-09 2002-09-17 Aventis Pharma S.A. Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase
FR2810037B1 (fr) * 2000-06-09 2004-04-23 Aventis Pharma Sa Utilisation de derives de 2-aminothiazoline comme inhibiteurs de no-synthase inductible
FR2832152A1 (fr) * 2001-11-09 2003-05-16 Aventis Pharma Sa Utilisation de derives de 2-amino-thiazoline comme inhibiteurs de no-synthase inductible
FR2810036B1 (fr) * 2000-06-09 2004-04-23 Aventis Pharma Sa Derives de 4,5-dihydro-1,3-thiazol-2-ylamine, leur preparation et les compositions phamarceutiques les contenant
US6420566B2 (en) 2000-06-09 2002-07-16 Aventis Pharma S.A. Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof
GB0016169D0 (en) * 2000-06-30 2000-08-23 Univ London Diagnostic method
EP1305293A1 (de) * 2000-08-01 2003-05-02 Pharmacia Corporation Hexahydro-7-imino-1h-azepin-2-yl-hexansäure-derivate als inhibitoren der induzierbaren stickstoffmonoxid-synthase
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
EP1359885A4 (de) * 2001-01-25 2005-03-16 Gen Hospital Corp Nos-hemmer zur behandlung von falten
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE60233043D1 (de) * 2001-04-19 2009-09-03 Eisai R&D Man Co Ltd 2-iminoimidazolderivate
US6514960B1 (en) 2001-08-27 2003-02-04 Hedonist Biochemical Technologies Co., Ltd. Use of bismuth subgallate in inhibition of production of nitric oxide synthase
US20040235890A1 (en) * 2001-09-10 2004-11-25 Masaharu Komeno Remedies for allergic diseases
US6818659B2 (en) 2001-11-06 2004-11-16 Bristol-Myers Squibb Pharma, Inc. (2S)-2-amino-4-(2-amino-(3,4,5,6-tetrahydropyrimidin-4-yl) butanoyl and its use in cyclic and acyclic peptides
CA2465691C (fr) * 2001-11-09 2011-07-19 Aventis Pharma S.A. Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
FR2832151B1 (fr) * 2001-11-09 2004-12-17 Aventis Pharma Sa Utilisation de derives de 2-amino-4-heteroarylethyl-thiazoline comme inhibiteurs de no-synthase inductible
CA2465877C (fr) 2001-11-09 2009-12-29 Aventis Pharma S.A. Utilisation de derives de 2-amino-4-pyridylmethyl-thiazoline comme inhibiteurs de non-synthase inductible
FR2832150B1 (fr) * 2001-11-09 2004-07-16 Aventis Pharma Sa Utilisation de derives de 2-amino-4-pyridylmethyl-thiazoline comme inhibiteurs de no-synthase inductible
DE60209806T2 (de) 2001-11-09 2006-11-02 Aventis Pharma S.A. 2-amino-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase
AU2002238889A1 (en) * 2002-03-14 2003-09-22 Dainippon Pharmaceutical Co., Ltd. Nitrogen monoxide synthase inhibitors
AU2004218187C1 (en) * 2003-02-19 2011-04-07 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
JP2007501781A (ja) * 2003-08-07 2007-02-01 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 駆虫及び殺虫ピリミジン誘導体
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
SI2395002T1 (sl) 2005-11-08 2014-10-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto
CL2008000838A1 (es) * 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
PL2639223T3 (pl) * 2007-12-07 2017-09-29 Vertex Pharmaceuticals Incorporated Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
JP5512202B2 (ja) * 2009-09-14 2014-06-04 株式会社クラレ β，β−ジメチル−ε−カプロラクタムの製造方法
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
WO2011149349A1 (en) * 2010-05-26 2011-12-01 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof
CN103124745B (zh) * 2010-08-02 2014-10-29 陶氏环球技术有限责任公司 抑制乙烯基-芳基单体聚合的组合物和方法
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
CA2858720A1 (en) * 2011-12-12 2013-06-20 University Of Florida Research Foundation Nicotinic receptor targeted compounds and compositions
JP5681751B2 (ja) 2013-05-27 2015-03-11 花王株式会社 香料組成物
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
CN103965097A (zh) * 2014-05-22 2014-08-06 南开大学 一种2-哌啶酮的制备方法
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds
US10196328B2 (en) 2016-06-02 2019-02-05 Chevron Phillips Chemical Company Lp Catalyst systems and ethylene oligomerization method
EP3497102B1 (de) 2016-08-15 2022-12-07 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CN107021893A (zh) * 2017-05-05 2017-08-08 贵州师范学院 一类硫代酰铵盐离子液体及其制备方法
US10807921B2 (en) 2017-12-01 2020-10-20 Chevron Phillips Chemical Company Lp Catalyst systems and ethylene oligomerization method
CN112028837A (zh) * 2019-06-03 2020-12-04 鲁南制药集团股份有限公司 一种替吡嘧啶中间体化合物
EP4305033A1 (de) 2021-03-09 2024-01-17 Basf Se Tricyclische pestizide verbindungen
US11505513B1 (en) 2021-11-08 2022-11-22 Chevron Phillips Chemical Company, Lp Chromium bicyclic phosphinyl amidine complexes for tetramerization of ethylene
US11492305B1 (en) 2021-11-08 2022-11-08 Chevron Phillips Chemical Company, Lp Chromium phosphinyl hydroisoindole amidine complexes for tetramerization of ethylene
US11583843B1 (en) 2021-11-08 2023-02-21 Chevron Phillips Chemical Company, Lp Chromium phosphinyl isoindole amidine complexes for tetramerization of ethylene

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2049582A (en) * 1931-11-04 1936-08-04 Rohm & Haas Amidines
US3109848A (en) * 1961-03-30 1963-11-05 Rohm & Haas Substituted iminopyrrolines and iminopyrrolidines
US3132151A (en) * 1961-05-15 1964-05-05 Rohm & Haas Specific substituted iminopyrrolidines
US3121093A (en) * 1962-08-31 1964-02-11 Rohm & Haas Substituted iminopyrrolidines
DE1670859A1 (de) * 1967-04-24 1971-03-11 Bayer Ag Verfahren zur Herstellung von 2-Phenyl-imino-1-azacycloalkanen
US3501487A (en) * 1967-06-29 1970-03-17 Mcneilab Inc Certain hetero-aryl lower alkylene derivatives of 1 - lower alkyl - 2-imino-pyrrolidines
US3725435A (en) * 1970-11-05 1973-04-03 Mc Neil Labor Inc 2-imino-pyrrolidines
US3694432A (en) * 1971-03-01 1972-09-26 Searle & Co 2-benzyloxyimino cyclic amines
ZA722407B (en) * 1971-05-13 1973-01-31 Richardson Merrell Inc Substituted cycloalkyl lactamimides
FR2186236B1 (de) * 1972-05-03 1975-08-01 Logeais Labor Jacques
US3816457A (en) * 1973-01-05 1974-06-11 Richardson Merrell Inc Lactamimide derivatives
US4153235A (en) * 1973-08-09 1979-05-08 Richardson-Merrell Inc. Substituted cycloalkyl lactamimides
US4046909A (en) * 1974-08-22 1977-09-06 Mcneil Laboratories, Incorporated Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants
US4061746A (en) * 1976-04-23 1977-12-06 Richardson-Merrell Inc. Lactamimide inhibitors of gastrointestinal hypersecretion
FR2431494A1 (fr) * 1978-07-17 1980-02-15 Logeais Labor Jacques Nouveaux derives du benzofuranne, leur procede de preparation et leur application en therapeutique
NZ197385A (en) * 1980-06-16 1984-08-24 Mcneilab Inc Phenylureas and pharmaceutical compositions
US4533739A (en) * 1982-10-12 1985-08-06 G. D. Searle & Co. 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity
FR2540109B1 (fr) * 1983-01-28 1985-08-30 Logeais Labor Jacques Imino-2 pyrrolidines, leur procede de preparation et leurs applications en therapeutique
US4525476A (en) * 1983-05-26 1985-06-25 Warner-Lambert Company N-[1-oxo-3-(5-oxo-2-pyrrolidinyl)propyl]-alpha-aminoacids and derivatives as cognition activators
US4523020A (en) * 1983-11-10 1985-06-11 G. D. Searle & Co. Substituted 2-(3-aminophenoxymethyl)imidazolines
US4579951A (en) * 1984-03-19 1986-04-01 G. D. Searle & Co. Substituted (azacycloalk-2-yl)iminophenols and esters thereof
US4812161A (en) * 1984-08-08 1989-03-14 Nippon Soda Co., Ltd. Thia (oxa) diazole derivatives
US4880827A (en) * 1986-03-18 1989-11-14 Sumitomo Pharmaceuticals Company, Ltd. Pyrrolidine derivatives having inhibitory action for proline specific endopepidase
DE3631414A1 (de) * 1986-09-16 1988-03-24 Basf Ag Verfahren zur herstellung von (alpha)-pyrrolidonen, deren verwendung und neue (alpha)-pyrrolidone
IT8721978A0 (it) * 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US5196439A (en) * 1987-11-27 1993-03-23 Eisai Co., Ltd. Piperidine compounds useful to treat cerebrovascular diseases
AU619613B2 (en) * 1988-11-10 1992-01-30 Merrell Dow Pharmaceuticals Inc. Lactamimides in the treatment of drug-resistant protozoal infections
CA1273380A (en) * 1989-07-24 1990-08-28 Frank Van Oirschot Inline venturi for pneumatic conveying systems
US5059712A (en) * 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5028627A (en) * 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation
AU636713B2 (en) * 1990-02-26 1993-05-06 Merrell Dow Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
IT1247697B (it) * 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti 3-ammino-e-caprolattami per il potenziamento dei processi di apprendimento e della memoria.
US5273875A (en) * 1991-03-22 1993-12-28 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5132453A (en) * 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
US5281627A (en) * 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof
US5362747A (en) * 1992-11-25 1994-11-08 Abbott Laboratories 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide synthase
SI9300616A (en) * 1992-11-27 1994-06-30 Wellcome Found Enzyme inhibitors
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
WO1994016729A1 (en) * 1993-01-28 1994-08-04 Neorx Corporation Targeted nitric oxide pathway or nitric oxide synthase modulation
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
PL180081B1 (pl) * 1993-08-12 2000-12-29 Astra Ab Nowe pochodne amidyny i sposób ich wytwarzania PL PL PL PL PL PL PL
WO1995010266A1 (en) * 1993-10-13 1995-04-20 Otsuka Pharmaceutical Co., Ltd. Nitrogen monoxide synthesis inhibitor
DE69416848T2 (de) * 1993-10-21 1999-07-08 Searle & Co Amidino-derivate als no-synthetase inhibitoren
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
DE4418097A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
US5621004A (en) * 1994-06-03 1997-04-15 Robert W. Dunn Method for treating emesis
WO1996014842A1 (en) * 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
US5629322A (en) * 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
CA2163399A1 (en) * 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
DE4442116A1 (de) * 1994-11-25 1996-05-30 Cassella Ag 2-Amino-1,3-thiazine als Hemmstoffe der Stickstoffmonoxid-Synthase
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JPH08333258A (ja) * 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
AU712315B2 (en) * 1995-04-20 1999-11-04 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
JP3188715B2 (ja) * 1995-11-01 2001-07-16 メルク エンド カンパニー インコーポレーテッド 一酸化窒素シンターゼの阻害物質としてのヘキサヒドロ−５−イミノ−１，４−ヘテロアゼピン誘導体

Also Published As

Publication number Publication date
KR960705777A (ko) 1996-11-08
RU2136661C1 (ru) 1999-09-10
EP0724570B1 (de) 1999-03-03
NO961403L (no) 1996-04-09
AU8081194A (en) 1995-05-08
KR100342275B1 (ko) 2002-12-05
CN1077886C (zh) 2002-01-16
NO309303B1 (no) 2001-01-15
US5854234A (en) 1998-12-29
AU688811B2 (en) 1998-03-19
EP0724570A1 (de) 1996-08-07
CN1137268A (zh) 1996-12-04
US6448286B1 (en) 2002-09-10
DK0724570T3 (da) 1999-09-27
WO1995011231A1 (en) 1995-04-27
CA2173468A1 (en) 1995-04-27
US6071906A (en) 2000-06-06
EP0897912A1 (de) 1999-02-24
US6046211A (en) 2000-04-04
ES2129679T3 (es) 1999-06-16
NO961403D0 (no) 1996-04-09
DE69416848D1 (en) 1999-04-08
JPH09504028A (ja) 1997-04-22
GR3030167T3 (en) 1999-08-31
DE69416848T2 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
DE69416848T2 (de) Amidino-derivate als no-synthetase inhibitoren
ES2175624T3 (es) Derivados de pirazolo(4,3-d)pirimidina y composiciones farmaceuticas que los contienen.
ATE345339T1 (de) N-heterocyclische derivate als nos inhibitoren
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
PH30006A (en) 9-¬(Substituted glycol)amido¾-6.demethyl-6-deoxytetra-cyclines
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
PT618190E (pt) 9-¬glicil substituido)amido|-6-(substituido)-5-hidroxi-6-desoxitetraciclinas
IL94915A (en) Substituted quinazolinones and pharmaceutical compositions containing them
DE69516141D1 (de) Enzymhemmer
DE69628804D1 (de) Substitutierte heterozyclische Derivate als CRF Antagonisten
DK0471236T3 (da) Imidazopyridinderivater og deres anvendelse
ES2181726T3 (es) Amidinoderivados utiles como inhibidores de oxido nitrico sintasa.
DE69703201T2 (de) Hydroxyamidinderivate verwendbar als stickoxidsynthese inhibitoren
TW280813B (de)
ES2104174T3 (es) Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos.
ATE282608T1 (de) Chinoxalindionen
ATE171622T1 (de) Antiallergische zusammensetzung enthaltend eine phosphorsäurediester-verbindung
DK656889D0 (da) Hidtil ukendte forbindelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee